PMID- 12350510
OWN - NLM
STAT- MEDLINE
DCOM- 20021115
LR  - 20190714
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
VI  - 60
IP  - 3
DP  - 2002 Sep
TI  - An Escherichia coli-based oral vaccine against urinary tract infections potently 
      activates human dendritic cells.
PG  - 521-6
AB  - OBJECTIVES: To investigate the effects of Uro-Vaxom, an oral vaccine against 
      Escherichia coli urinary tract infections, on human monocyte-derived dendritic 
      cells (moDCs). Dendritic cells (DCs) are important antigen-presenting cells of 
      the immune system. DCs are considered promising cellular adjuvants for inducing 
      immunity against cancer or infectious diseases. METHODS: moDCs were generated in 
      the presence of granulocyte-macrophage colony-stimulating factor and 
      interleukin-4. Flow cytometric phenotyping, as well as the ability to stimulate T 
      cells in an allogeneic mixed leukocyte reaction, was used to assess the effects 
      of Uro-Vaxom on human moDCs. In addition, interferon-gamma and interleukin-4 
      production by T cells stimulated with Uro-Vaxom-activated moDCs were measured by 
      intracellular fluorescence-activated cell sorter-staining at the single-cell 
      level. RESULTS: Uro-Vaxom induced the terminal maturation of CD83+ moDCs in a 
      dose-dependent manner. Phenotypic analyses revealed that Uro-Vaxom-activated 
      moDCs displayed a phenotype of mature DCs with high levels of MHC molecules and 
      increased levels of co-stimulatory molecules (CD80, CD86). Consistent with these 
      findings, Uro-Vaxom-activated moDCs potently stimulated T-cell proliferation and 
      interferon-gamma production in the allogeneic mixed leukocyte reaction. 
      CONCLUSIONS: In DC-based immunotherapy, Uro-Vaxom could be used as a stimulant of 
      DC maturation, which meets the standards of good manufacturing practice. In 
      future preclinical studies, we will evaluate the effectiveness of a vaccination 
      with Uro-Vaxom-activated moDCs. It could be an attractive treatment option in 
      preventing recurrent E. coli urinary tract infections in predisposed individuals.
FAU - Schmidhammer, Silvia
AU  - Schmidhammer S
AD  - Department of Urology, University of Innsbruck, Innsbruck, Austria.
FAU - Ramoner, Reinhold
AU  - Ramoner R
FAU - Holtl, Lorenz
AU  - Holtl L
FAU - Bartsch, Georg
AU  - Bartsch G
FAU - Thurnher, Martin
AU  - Thurnher M
FAU - Zelle-Rieser, Claudia
AU  - Zelle-Rieser C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antigens, CD)
RN  - 0 (Escherichia coli Vaccines)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adjuvants, Immunologic/*pharmacology/therapeutic use
MH  - Antigens, CD/immunology
MH  - Cells, Cultured
MH  - Dendritic Cells/drug effects/*immunology
MH  - Dose-Response Relationship, Immunologic
MH  - Escherichia coli/immunology
MH  - Escherichia coli Infections/immunology/prevention & control
MH  - Escherichia coli Vaccines/*pharmacology/therapeutic use
MH  - Flow Cytometry
MH  - Humans
MH  - Immunophenotyping
MH  - Interferon-gamma/immunology
MH  - Lymphocyte Culture Test, Mixed
MH  - Monocytes/immunology
MH  - Urinary Tract Infections/immunology/prevention & control
EDAT- 2002/09/28 04:00
MHDA- 2002/11/26 04:00
CRDT- 2002/09/28 04:00
PHST- 2002/09/28 04:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/09/28 04:00 [entrez]
AID - S0090429502017673 [pii]
AID - 10.1016/s0090-4295(02)01767-3 [doi]
PST - ppublish
SO  - Urology. 2002 Sep;60(3):521-6. doi: 10.1016/s0090-4295(02)01767-3.